Carcinoma of the pancreas: Current status of multimodal therapy;Pankreaskarzinom: Aktueller Stand der multimodalen Therapie

Zentralblatt fur Chirurgie - Zeitschrift fur Allgemeine, Viszeral- und Gefasschirurgie

Volumn 136, Issue 4, 2011, Pages 352-358

  Keck, T ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

adjuvant therapy; chemotherapy; locally advanced disease; neoadjuvant therapy; pancreatic carcinoma; radiation therapy

Indexed keywords

ADJUVANT CHEMORADIOTHERAPY; ADJUVANT THERAPY; ARTICLE; CANCER INVASION; CANCER STAGING; HUMAN; MORTALITY; MULTIMODALITY CANCER THERAPY; PANCREAS RESECTION; PANCREAS TUMOR; PATHOLOGY; SURVIVAL RATE;

CHEMORADIOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; HUMANS; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PANCREATECTOMY; PANCREATIC NEOPLASMS; SURVIVAL RATE;

EID: 80052167305     PISSN: 0044409X     EISSN: 14389592     Source Type: Journal    
DOI: 10.1055/s-0031-1271563     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J Clin 2009 59 225-249
2. Sultana A, Tudur Smith C, Cunningham D et al. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses. Br J Cancer 2008 99 6-13 (Pubitemid 351920234)
3. Raut C P., Tseng J F., Sun C C. et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg 2007 246 52-60 (Pubitemid 47012207)
4. Shrikhande S V., Kleeff J, Reiser C et al. Pancreatic resection for M1 pancreatic ductal adenocarcinoma. Ann Surg Oncol 2007 14 118-127 (Pubitemid 44954278)
5. Adler G, Seufferlein T, Bischoff S C. et al. [S3-Guidelines Exocrine pancreatic cancer 2007]. Z Gastroenterol 2007 45 487-523 (Pubitemid 47056016)
6. Huser N, Assfalg V, Michalski C W. et al. [Unresectable pancreatic cancer palliative interventional and surgical treatment]. Zentralbl Chir 2010 135 502-507
7. Fietkau R, Heinemann V, Oettle H et al. [New data on pancreatic cancer]. Onkologie 2010 33 31-35
8. Menon K V., Gomez D, Smith A M. et al. Impact of margin status on survival following pancreatoduodenectomy for cancer: the Leeds Pathology Protocol (LEEPP). HPB (Oxford) 2009 11 18-24
9. Neoptolemos J P., Stocken D D., Friess H et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. New Engl J Med 2004 350 1200-1210 (Pubitemid 38339364)
10. Oettle H, Post S, Neuhaus P et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. Jama 2007 297 267-277 (Pubitemid 46143304)
11. Gillen S, Schuster T, Meyer Zum Buschenfelde C et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS medicine 2010 7 e1000267
12. Warnick P, Bahra M, Andreou A et al. [Second-look operation in pancreatic carcinoma previously assessed as unresectable]. Zentralbl Chir 2010 135 70-74
13. Tempero M, Arnoletti J P., Ben-Josef E et al. Pancreatic adenocarcinoma. Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2007 5 998-1033
14. Tseng J F., Raut C P., Lee J E. et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg 2004 8 935-949 discussion 949-950
15. Yekebas E F., Bogoevski D, Cataldegirmen G et al. En bloc vascular resection for locally advanced pancreatic malignancies infiltrating major blood vessels: perioperative outcome and long-term survival in 136patients. Ann Surg 2008 247 300-309 (Pubitemid 351156774)
16. Leach S D., Lee J E., Charnsangavej C et al. Survival following pancreaticoduodenectomy with resection of the superior mesenteric-portal vein confluence for adenocarcinoma of the pancreatic head. Br J Surg 1998 85 611-617 (Pubitemid 28247531)
17. Riediger H, Makowiec F, Fischer E et al. Postoperative morbidity and long-term survival after pancreaticoduodenectomy with superior mesenterico-portal vein resection. J Gastrointest Surg 2006 10 1106-1115 (Pubitemid 44332981)
18. Siriwardana H P., Siriwardena A K. Systematic review of outcome of synchronous portal-superior mesenteric vein resection during pancreatectomy for cancer. Br J Surg 2006 93 662-673 (Pubitemid 43886017)
19. Riess H NP, Post S, Gellert K et al. CONKO-001: final results of the randomized, prospective multicenter phase III trial of adjuvant chemotherapy versus observation in patients with resected pancreatic cancer (PC). In: 33rd European Society for Medical Oncology Congress Stockholm Oxford University Press 2008 45-46
20. Esposito I, Kleeff J, Bergmann F et al. Most pancreatic cancer resections are R1 resections. Ann Surg Oncol 2008 15 1651-1660
21. Regine W F., Winter K A., Abrams R A. et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. Jama 2008 299 1019-1026 (Pubitemid 351347058)
22. Khanna A, Walker G R., Livingstone A S. et al. Is adjuvant 5-FU-based chemoradiotherapy for resectable pancreatic adenocarcinoma beneficial? A meta-analysis of an unanswered question. J Gastrointest Surg 2006 10 689-697 (Pubitemid 43732383)
23. Yeo C J., Cameron J L., Sohn T A. et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg 1997 226 248-257 discussion 257-260
24. Stocken D D., Buchler M W., Dervenis C et al. Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer 2005 92 1372-1381 (Pubitemid 40705002)
25. Kalser M H., Ellenberg S S. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985 120 899-903 (Pubitemid 15040883)
26. Klinkenbijl J H., Jeekel J, Sahmoud T et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phaseIII trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999 230 776-782 discussion 782-784
27. Loehrer P, Powell M, Cardenes H et al. A randomized phase II study of gemcitambine in combination with radiation therapy versus gemcitabine alone in patients with localizes, unresectable pancreatic cancer: E4201. J Clin Oncol 2008 26 4506a
28. Bertout J A., Patel S A., Simon M C. The impact of O2 availability on human cancer. Nat Rev Cancer 2008 8 967-975
29. Golcher H, Brunner T, Grabenbauer G et al. Preoperative chemoradiation in adenocarcinoma of the pancreas. A single centre experience advocating a new treatment strategy. Eur J Surg Oncol 2008 34 756-764
30. Snady H, Bruckner H, Cooperman A et al. Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer 2000 89 314-327 (Pubitemid 30489879)
31. White R R., Hurwitz H I., Morse M A. et al. Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann Surg Oncol 2001 8 758-765 (Pubitemid 34003323)
32. Morganti A G., Massaccesi M, La Torre G et al. A systematic review of resectability and survival after concurrent chemoradiation in primarily unresectable pancreatic cancer. Ann Surg Oncol 2010 17 194-205
33. Bang S, Chung H W., Park S W. et al. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer. J Clin Gastroenterol 2006 40 923-929 (Pubitemid 44690768)